[1]LANG M,VOCKE CD,RICKETTS CJ,et al.Clinical and molecular characterization of microphthalmia-associated transcription factor(MITF)-related renal cell carcinoma ［J］.Urology,2021,149:89-97.
[2]BOUCHE V,ESPINOSA AP,LEONE L,et al.Drosophila Mitf regulates the V-ATPase and the lysosomal-autophagic pathway ［J］.Autophagy,2016,12(3):484-498.
[3]NEHA,DAS P,VERMA SP.Dual role of G-quadruplex in translocation renal cell carcinoma:Exploring plausible Cancer therapeutic innovation ［J］.Biochimica et Biophysica Acta General Subjects,2020,1864(12):129719.
[4]BABA M,FURUYA M,MOTOSHIMA T,et al.TFE3Xp11.2 translocation renal cell carcinoma mouse model reveals novel therapeutic targets and identifies GPNMB as a diagnostic marker for human disease ［J］.Molecular Cancer Research,2019,17(8):1613-1626.
[5]SUN G,CHEN J,LIANG J,et al.Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma ［J］.Nature Communications,2021,12(1):5262.
[6]GE Y,LIN X,ZHANG Q,et al.Xp11.2 translocation renal cell carcinoma with TFE3 rearrangement:Distinct morphological features and prognosis with different fusion partners ［J］.Frontiers in Oncology,2021:4976.
[7]KUENTZ MA,BLONS H,GIMENEZ-ROQUEPLO AP,et al.A novel VCP:TFE3 gene fusion resulting from t(X;9)(p11.23;p13.3) chromosome translocation in TFE3 rearranged renal cancer cell carcinoma ［J］.Genes,Chromosomes & Cancer,2023,62(6):361-366.
[8]GUO W,ZHU Y,PU X,et al.Clinical and pathological heterogeneity of four common fusion subtypes in Xp11.2 translocation renal cell carcinoma ［J］.Frontiers in Oncology,2023,13:1116648.
[9]XIE L,ZHANG Y,WU CL.Microphthalmia family of transcription factors associated renal cell carcinoma ［J］.Asian Journal of Urology,2019,6(4):312-320.
[10]ARGANI P.Translocation carcinomas of the kidney ［J］.Genes,Chromosomes & Cancer,2022,61(5):219-227.
[11]ZHUANG W,DONG X,WANG B,et al.NRF-1 directly regulates TFE3 and promotes the proliferation of renal cancer cells ［J］.Oncology Letters,2021,22(3):679.
[12] LINEHAN W M,SCHMIDT LS,CROOKS DR,et al.The metabolic basis of kidney cancer ［J］.Cancer Discovery,2019，9(8): 1006-1021.
[13]DONG X,CHEN Y,PAN J,et al.Clinicopathological features and prognosis of TFE3-positive renal cell carcinoma ［J］.Frontiers in Oncology,2022,12(1017425).
[14]AKGUL M,SAEED O,LEVY D,et al.Morphologic and Immunohistochemical characteristics of fluorescent in situ hybridization confirmed TFE3-gene fusion associated renal cell carcinoma: A single institutional cohort ［J］.The American Journal of Surgical Pathology,2020,44(11):1450-1458.
[15] LEE HJ,SHIN DH,KIM SY,et al.TFE3 translocation and protein expression in renal cell carcinoma are correlated with poor prognosis ［J］.Histopathology,2018,73(5):758-766.
[16] FANG Y,BAO W,RAO Q,et al.TFE3 regulates renal adenocarcinoma cell proliferation via activation of the mTOR pathway ［J］.Molecular Medicine Reports,2017,16(3):2721-2725.
[17] APONTE-LOPEZ A,MUNOZ-CRUZ S.Mast cells in the tumor microenvironment ［J］.Advances in Experimental Medicine and Biology,2020,1273:159-173.
[18] SANG J,YI D,TANG X,et al.The associations between mast cell infiltration,clinical features and molecular types of invasive breast cancer ［J］.Oncotarget,2016,7(49):81661-81669.
[19] RAJPUT AB,TURBIN DA,CHEANG MC,et al.Stromal mast cells in invasive breast cancer are a marker of favourable prognosis:a study of 4,444 cases ［J］.Breast Cancer Research and Treatment,2008,107(2):249-257.
[20] SHIKOTRA A,OHRI CM,GREEN RH,et al.Mast cell phenotype,TNFα expression and degranulation status in non-small cell lung cancer ［J］.Scientific Reports,2016,6:38352.
[21] WELSH TJ,GREEN RH,RICHARDSON D,et al.Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer ［J］.Journal of Clinical Oncology,2005,23(35):8959-8967.
[22] GLAJCAR A,SZPOR J,PACEK A,et al.The relationship between breast cancer molecular subtypes and mast cell populations in tumor microenvironment ［J］.Virchows Archiv,2017,470(5):505-515.
[23] HEMPEL SULLIVAN H,HEAPHY CM,KULAC I,et al.High extratumoral mast cell counts are associated with a higher risk of adverse prostate cancer outcomes ［J］.Cancer Epidemiology,Biomarkers & Prevention,2020,29(3):668-675.
[24] JOHANSSON A,RUDOLFSSON S,HAMMARSTEN P,et al.Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy ［J］.The American Journal of Pathology,2010,177(2):1031-1041.
[25] FLEISCHMANN A,SCHLOMM T,KOLLERMANN J,et al.Immunological microenvironment in prostate cancer:high mast cell densities are associated with favorable tumor characteristics and good prognosis ［J］.The Prostate,2009,69(9):976-981.
[26] ZHAO SG,LEHRER J,CHANG SL,et al.The immune landscape of prostate cancer and nomination of PD-L2 as a potential therapeutic target ［J］.Journal of the National Cancer Institute,2019,111(3):301-310.
[27] CHANG DZ,MA Y,JI B,et al.Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma ［J］.Clinical Cancer Research,2011,17(22):7015-7023.
[28] STROUCH MJ,CHEON EC,SALABAT MR,et al.Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression ［J］.Clinical Cancer Research,2010,16(8):2257-2265.
[29] MAO Y,FENG Q,ZHENG P,et al.Low tumor infiltrating mast cell density confers prognostic benefit and reflects immunoactivation in colorectal cancer ［J］.International Journal of Cancer,2018,143(9):2271-2280.
[30] GULUBOVA M,VLAYKOVA T.Prognostic significance of mast cell number and microvascular density for the survival of patients with primary colorectal cancer ［J］.Journal of Gastroenterology and Hepatology,2009,24(7):1265-1275.
[31] AMMENDOLA M,SACCO R,ZUCCALA V,et al.Mast cells density positive to tryptase correlate with microvascular density in both primary gastric cancer tissue and loco-regional lymph node metastases from patients that have undergone radical surgery ［J］.International Journal of Molecular Sciences,2016,17(11):1905.
[32] YAO J,XI W,CHEN X,et al.Mast cell density in metastatic renal cell carcinoma:Association with prognosis and tumour-infiltrating lymphocytes ［J］.Scandinavian Journal of Immunology,2021,93(4):e13006.
[33] SAURA-ESTELLER J,DE JONG M,KING LA,et al.Gamma delta T-cell based cancer immunotherapy:Past-present-future ［J］.Frontiers in Immunology,2022,13:915837.
[34] ADAMS EJ,GU S,LUOMA AM.Human gamma delta T cells:Evolution and ligand recognition ［J］.Cellular Immunology,2015,296(1):31-40.
[35] XIA Y,RAO L,YAO H,et al.Engineering macrophages for cancer immunotherapy and drug delivery ［J］.Advanced Materials (Deerfield Beach,Fla),2020,32(40):e2002054.
[36] OHUE Y,NISHIKAWA H.Regulatory T (Treg) cells in cancer:Can Treg cells be a new therapeutic target［J］.Cancer Science,2019,110(7):2080-2089.
[37] 张朝华,赵春利.肾癌患者外周血和肿瘤组织内Treg细胞比例与预后的关系 ［J］.中国药业,2010,19(18):30-31.
ZHANG CH,ZHAO CL.Relationship between the proportion of Treg cells in peripheral blood and tumor tissue and prognosis in patients with renal cell carcinoma［J］.China Pharmaceutical,2010,19(18):30-31.
[38] SAITO T,NISHIKAWA H,WADA H,et al.Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers ［J］.Nature Medicine,2016,22(6):679-684.
[39] LU M,ZHAO B,LIU M,et al.Pan-cancer analysis of SETD2 mutation and its association with the efficacy of immunotherapy ［J］.NPJ precision Oncology,2021,5(1):51.
[40] QIAO Z,JIANG Y,WANG L,et al.Mutations in KIAA1109,CACNA1C,BSN,AKAP13,CELSR2,and HELZ2 are associated with the prognosis in endometrial cancer ［J］.Frontiers in Genetics,2019,10:909.
[41] QING T,ZHU S,SUO C,et al.Somatic mutations in ZFHX4 gene are associated with poor overall survival of Chinese esophageal squamous cell carcinoma patients ［J］.Scientific Reports,2017,7(1):4951.
[42] WILLIAMSON SR,GILL AJ,ARGANI P,et al.Report from the international society of urological pathology(ISUP) consultation conference on molecular pathology of urogenital cancers:III:Molecular pathology of kidney cancer ［J］.The American Journal of Surgical Pathology,2020,44(7):e47-e65.
[43] LINEHAN WM,SPELLMAN PT,RICKETTS CJ,et al.Comprehensive molecular characterization of papillary renal-cell carcinoma ［J］.The New England Journal of Medicine,2016,374(2):135-145.
[44] CARRIL-AJURIA L,SANTOS M,ROLDAN-ROMERO JM,et al.Prognostic and predictive value of PBRM1 in clear cell renal cell carcinoma ［J］.Cancers,2019,12(1):16.
[45] BRAUN DA,ISHII Y,WALSH AM,et al.Clinical validation of PBRM1 alterations as a marker of immune checkpoint inhibitor response in renal cell carcinoma ［J］.JAMA Oncology,2019,5(11):1631-1633.
[46] TAKAMATSU D,KOHASHI K,KIYOZAWA D,et al.TFE3-immunopositive papillary renal cell carcinoma:A clinicopathological,immunohistochemical,and genetic study ［J］.Pathology,Research and Practice,2023,242:154313.
[47] TANG J,BABA M.MiT/TFE family renal cell carcinoma ［J］.Genes,2023,14(1):151.